

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Keyong REN et al.

Serial No.:

10/776,433

Filed: February 11, 2004

For:

INHIBITION OF CYP450 1A2, 2A6, 2C9, 2C19,

2D6, 2E1, AND 3A4 IN CRYOPRESERVED **HUMAN**

HEPATOCYTES

BY

F.

TRIPTERYGIUM WILFORDII HOOK.

EXTRACT

Examiner:

Group Art:

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 13, 2004

(Date of Deposit)

Yunling Ren
no of applicant, assignee or Registered Representative

Signature

July 13, 2004 Date of Signature

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO/SB/08A. Copies of the listed documents are also enclosed.

It is respectfully requested that the above information be considered by the Examiner and that the copy of the enclosed Form PTO/SB/08A be returned indicating that such information has been considered.

In accordance with 37 C.F.R §§1.97(g) and (h), the filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserve(s) the right to prove that the date of publication is in fact different.

If any fees or charges are deemed required at this time in connection with the application, the same may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

> Respectfully submitted, COHEN, PONTANI, LIEBERMAN & PAVANE

hling Ren

Reg. No. 47,019

551 Fifth Avenue, Suite 1210

New York, New York 10176

(212) 687-2770

Dated: July 13, 2004

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the flaperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/PTO	Com	Complete if Known		
ADEMAN:	Application Number	10/776,433		
INFORMATION DISCLOSUR	Filing Date	February 11, 2004		
STATEMENT BY APPLICANT	First Named Inventor	Keyong REN		
(Use as many sheets as necessary)	Art Unit	1654		
(est to many thous as hecessary)	Examiner Name			
Sheet 1 of 2	Attorney Docket Number	5155-7CIP		

			U.S. PATE	NT DOCUMENTS	
Examiner Initials*	Cite No. 1	Document Number Number-Kind-Code ^{2 (if known)}	Publication Date - MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
		US-	-		
		US-			
_		US-			
		US-			

		F	OREIGN PA	TENT DOCUMENTS		
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	Te
minais	NO.	Country Code ³⁻ Number ⁴⁻ Kind-Code ^{5 (if known}	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	
· · · ·						

Examiner Date	
Signature Considered	
Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute f	or Form 1449/PTO			C	omplete if Known	
				Application Number	10/776,433	
INFORMATION DISCLOSURE				Filing Date	February 11, 2004	
				First Named Inventor	Keyong REN	,
STATEMENT BY APPLICANT (Use as many sheets as necessary)				Art Unit		
	(Ose as many si	iccis as i	iecessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	5155-7CIP	

Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	l T ²
No. 1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1
	Li et al., Cyopreserved human hepatocytes: characterization of drug-	
	metabolizing enzyme activities and applications in higher throughput	
	screening assays for hepatotoxicity, metabolic stability, and drug-drug	
		\top
	Culture Methods 14, 139-146 (1992).	
	Loretz et al., Optimization of cryopreservation procedures for rat and	T
	human hepatocytes., Xenobiotica 19(5), 489-498.	
	Ruegg et al, Cytochrome-P450 induction and conjugated metabolism in	
		\top
		
		<u> </u>
		-
	·	
	Date Considered	
	No.	Li et al., Cyopreserved human hepatocytes: characterization of drugmetabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential, Chem. Biol. Interact. 121, 17-35 (1999). Li et al., Isolation and culturing of hepatocytes from human livers., J. Tiss. Culture Methods 14, 139-146 (1992). Loretz et al., Optimization of cryopreservation procedures for rat and human hepatocytes., Xenobiotica 19(5), 489-498. Ruegg et al, Cytochrome-P450 induction and conjugated metabolism in primary human hepatocytes after cryopreservation., In Vitro Toxicol. 10(2), 217-222 (1997).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.